Non-Hodgkin Lymphoma

The addition of orelabrutinib to sintilimab demonstrated good efficacy with a rapid time to response in patients with relapsed/refractory primary central nervous system lymphoma.

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

The FDA has granted an orphan drug designation to the CD20-targeted autologous CAR T-cell therapy, MB-106, for use as a potential therapeutic option in patients with Waldenström macroglobulinemia.

Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

The European Medicines Agency has verified its type II variation application to extend the indication for lisocabtagene maraleucel to include the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma, who are refractory or have relapsed within 12 months of initial therapy and are candidates for hematopoietic stem cell transplant.

The combination of epcoritamab and R-CHOP produced high overall response rates and complete metabolic response rates with a manageable toxicity profile in patients with diffuse large B-cell lymphoma.

The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.

Zandelisib, a potent and selective oral PI3Kδ inhibitor, elicited a high overall response rate as a single agent in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to data from the phase 2 TIDAL trial.

The combination of obinutuzumab plus chemotherapy delivered superior long-term progression-free survival benefit for patients with treatment-naïve follicular lymphoma.

Treatment with the R-CODOX-M and R-IVAC regimens elicited similar efficacy to dose-adjusted infused DA-EPOCH-R in patients with newly diagnosed, high-risk Burkitt lymphoma.

The first-in-class, subcutaneously administered T-cell–engaging bispecific antibody epcoritamab demonstrated deep and durable responses in patients with relapsed/refractory large B-cell lymphoma.

The European Commission has granted a conditional marketing authorization for mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 systemic therapies.

The addition of zanubrutinib to obinutuzumab achieved an improved overall response rate, overall survival, and progression-free survival, compared with obinutuzumab alone, in patients with relapsed/refractory follicular lymphoma.

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

The FDA announced that it has withdrawn approval for umbralisib, an oral inhibitor of PI3K-δ and CK1-ε manufactured by TG Therapeutics.

Nurix Therapeutics has initiated an ongoing phase 1 trial to examine NX-2127, an immunomodulatory oral BTK inhibitor, in patients with chronic lymphocytic leukemia.

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.

The European Commission has approved the combination of polatuzumab vedotin and rituximab and cyclophosphamide, doxorubicin, and prednisone for use in adult patients with previously untreated diffuse large B-cell lymphoma.

The European Commission has approved the CD19-targeting chimeric antigen receptor T-cell agent tisagenlecleucel for the treatment of adults with relapsed/refractory follicular lymphoma following at least 2 lines of systemic therapy.

New research illuminates the mechanisms that make B-cell lymphomas resistant to important immunotherapy

Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.